The partnership between Qiagen and NeoGenomics, a provider of cancer-focused genetic testing services, will ensure Day-One patient access to FDA-approved molecular tests paired with newly approved drugs for cancer.
Building on the US Food and Drug Administration's modernized regulatory approach to advanced diagnostics, especially next-generation sequencing tests, the collaboration with NeoGenomics will allow Qiagen and pharmaceutical partners to streamline the development and launch of targeted drugs and companion diagnostics to guide treatment decisions.
The partnership offers flexible pathways leading to introduction of FDA-approved companion diagnostics simultaneously with launch of new therapies.
Qiagen and NeoGenomics will discuss their efforts to expedite access for precision medicine solutions at the American Society of Hematology 2018 annual meeting and Exposition from December 1-4, 2018, in San Diego.
NeoGenomics has a national footprint and broad customer reach in cancer-related genetic testing services and one of the most comprehensive oncology-focused test menus.
The master service agreement provides a flexible framework with multiple options for co-development, verification, setup, and launch of new companion diagnostics, including next-generation sequencing tests, for biomarker profiling paired with new targeted drugs.
As Qiagen collaborates with pharma and biotech partners, co-development progresses from drug discovery and creation of a biomarker test, to clinical development evaluating the proposed drug and test, to validation for clinical use and then commercialization of the new drug and companion diagnostic.
Commercial alignment and launch readiness for companion diagnostics at the time of drug approval have become increasingly important for Qiagen's´s pharmaceutical partners.
Qiagen, a Netherlands-based holding company, is a provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life.
Its sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis.
Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows.
NeoGenomics specialises in cancer genetics testing and information services.
Headquartered in Fort Myers, Florida, NeoGenomics operates CLIA-certified laboratories in Aliso Viejo and Fresno, California; Tampa and Fort Myers, Florida; Houston, Texas; Nashville, Tennessee, and Rolle, Switzerland.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval